2020-02-20 08:51:20

Consolidated Research Feed

Isofol Medical: Fully focused on AGENT - DNB

"Q4’s operating loss was higher than expected, mainly due to continued higher R&D spending as well as costs related to the change of CEO. The 005-study has been concluded and the company’s full attention should now be on bringing arfolitixorin to market. We estimate continued high R&D spending going forward as more sites are expected to be opened. We have tweaked our estimated fair value to SEK14–42 (SEK18–49)."

Link to commissioned research below.
https://www.dnb.no/seg-fundamental/fundamentalweb/GetReportSpon.aspx?file=CMPSP_151183.pdf

Commissioned research feed

Isofol Medical
analytics consolidatedresearch crfdnb healthcare lifescience pharmaceuticals share stocks